Creating the Prescription Drug Affordability Board
HB2831 would create the West Virginia Prescription Drug Affordability Board and a related Prescription Drug Affordability Stakeholder Council to study drug pricing and identify prescription drugs that create affordability challenges for the state health care system and patients. The board would be composed of five primary members appointed by statewide officials, with alternate members for recusals, and would be staffed by an executive director and support staff. The bill also sets out conflict-of-interest rules, open meeting requirements, confidentiality protections for nonpublic pricing data, and ethics obligations for board members, staff, and contractors.
The board would be tasked with collecting transparency data, reviewing prescription drug products that meet specified price thresholds or price-increase triggers, and determining whether to conduct a cost review. If a review is undertaken, the board would examine factors such as wholesale acquisition cost, rebates, patient access, therapeutic alternatives, and manufacturer pricing justifications. The bill also requires periodic reports to the Governor and legislative committees, including recommendations for additional legislation and a broader study of the pharmaceutical distribution and payment system by the end of 2028.
The bill would add a new article to the West Virginia Code establishing a new regulatory and advisory structure focused on prescription drug affordability. It would authorize the board to collect data, adopt regulations, request information from manufacturers and other market participants, and potentially set upper payment limits for certain prescription drugs purchased or paid for by state and local government entities, subject to approval procedures and limitations for drugs on the federal shortage list. It would also create a special non-lapsing Prescription Drug Affordability Fund financed by annual fees on manufacturers, pharmacy benefit managers, insurers, and wholesale distributors, capped at $2 million per year.
The bill’s structure suggests a policy goal of lowering prescription drug costs and increasing transparency, and the committee caption indicates a straightforward effort to create a Prescription Drug Affordability Board. Because no committee transcripts or recorded votes were provided, there is no documented floor or committee debate to gauge support or opposition. Based on the text alone, the bill appears designed as a consumer- and purchaser-protection measure with significant regulatory oversight, which typically attracts support from affordability advocates and scrutiny from industry stakeholders.
The main points of contention are likely to be the board’s authority to review pricing data, compel information from manufacturers and intermediaries, and potentially impose upper payment limits on drugs purchased by government programs. Drug manufacturers, pharmacy benefit managers, insurers, and wholesale distributors may object to the fee structure, confidentiality provisions, and the possibility of price controls or compelled disclosure of proprietary information. Supporters are likely to emphasize lower costs, transparency, and protection for patients, state agencies, and public health purchasers, while critics may focus on administrative burden, market interference, and the risk of unintended supply disruptions.